Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Seoul, South Korea. In J Thorac Oncol, 31 Aug 2015
Within the KRAS-negative cases, we found numerous potentially targetable gene fusions and mutations, including CD74-NRG1, VAMP2-NRG1, TRIM4-BRAF, TPM3-NTRK1, and EML4-ALK gene fusions and ERBB2, BRAF, and PIK3CA mutations.
Molecular basis of claudin-17 anion selectivity.
Berlin, Germany. In Cell Mol Life Sci, 21 Aug 2015
In detail, we propose a hydrophilic furrow in the claudin-17 protomer spanning from a gap between the ends of TM2 and TM3 along R31, E48, and Y67 to a gap between K65 and S68 lining the anion channel.
Anchored multiplex PCR for targeted next-generation sequencing.
Boston, United States. In Nat Med, Dec 2014
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
Targeting tropomyosin-receptor kinase fused gene in cancer.
Taipei, Taiwan. In Anticancer Res, Apr 2014
Tropomyosin-receptor kinase fused gene (TRK-fused gene, TFG) encodes a protein which is a conserved regulator of protein secretion that localizes in the endoplasmic reticulum exit sites and controls the export of materials from the endoplasmic reticulum.
London, United Kingdom. In Handb Exp Pharmacol, 2013
Structurally, TRPV1 subunits have six transmembrane (TM) domains with intracellular N- (containing 6 ankyrin-like repeats) and C-termini and a pore region between TM5 and TM6 containing sites that are important for channel activation and ion selectivity.